Cortazar FB, Marrone KA, Troxell ML, Ralto KM, Hoenig MP, Brahmer JR, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int. 2016;90:638–47.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Cortazar FB, Kibbelaar ZA, Glezerman IG, Abudayyeh A, Mamlouk O, Motwani SS, et al. Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study. J Am Soc Nephrol. 2020;31:435–46.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Rao Ullur A, Côté G, Pelletier K, Kitchlu A. Immunotherapy in oncology and the kidneys: a clinical review of the evaluation and management of kidney immune-related adverse events. Clin Kidney J. 2023;16:939–51.

Article  PubMed  PubMed Central  Google Scholar 

Gupta S, Short SAP, Sise ME, Prosek JM, Madhavan SM, Soler MJ, et al. Acute kidney injury in patients treated with immune checkpoint inhibitors. J Immunother Cancer. 2021;9:e003467. https://doi.org/10.1136/jitc-2021-003467.

Article  PubMed  PubMed Central  Google Scholar 

Kitchlu A, Jhaveri KD, Wadhwani S, Deshpande P, Harel Z, Kishibe T, et al. A systematic review of immune checkpoint inhibitor-associated glomerular disease. Kidney Int Rep. 2021;6:66–77.

Article  PubMed  Google Scholar 

Brahmer JR, Abu-Sbeih H, Ascierto PA, Brufsky J, Cappelli LC, Cortazar FB, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021;9:e002435. https://doi.org/10.1136/jitc-2021-002435.

Article  PubMed  PubMed Central  Google Scholar 

Couey MA, Bell RB, Patel AA, Romba MC, Crittenden MR, Curti BD, et al. Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance. J Immunother Cancer. 2019;7:165.

Article  PubMed  PubMed Central  Google Scholar 

Wanchoo R, Karam S, Uppal NN, Barta VS, Deray G, Devoe C, et al. Adverse renal effects of immune checkpoint inhibitors: a narrative review. Am J Nephrol. 2017;45:160–9.

Article  PubMed  CAS  Google Scholar 

Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob J-J, Cowey CL, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377:1345–56.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Fogazzi GB, Ferrari B, Garigali G, Simonini P, Consonni D. Urinary sediment findings in acute interstitial nephritis. Am J Kidney Dis. 2012;60:330–2.

Article  PubMed  Google Scholar 

Muriithi AK, Leung N, Valeri AM, Cornell LD, Sethi S, Fidler ME, et al. Biopsy-proven acute interstitial nephritis, 1993–2011: a case series. Am J Kidney Dis. 2014;64:558–66.

Article  PubMed  Google Scholar 

Takahashi N, Tsuji K, Tamiya H, Shinohara T, Kuroda N, Takeuchi E. Goodpasture’s disease in a patient with advanced lung cancer treated with nivolumab: an autopsy case report. Lung Cancer. 2018;122:22–4.

Article  PubMed  Google Scholar 

Sammartino C, Goodman D, Flanagan G, Hill P. Anti-GBM disease following CTLA4 blockade in a patient with metastatic melanoma. Clin Kidney J. 2010;3:135–7.

Article  Google Scholar 

Hultin S, Nahar K, Menzies AM, Long GV, Fernando SL, Atkinson V, et al. Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report. BMC Nephrol. 2020;21:391.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kyriazis P, Tiwary A, Freeman J, Landry D, Braden G. Atypical anti-glomerular basement membrane glomerulonephritis in a patient with metastatic melanoma treated with mitogen-activated protein kinase and immune checkpoint inhibitors: a case report. J Med Case Rep. 2021;15:186.

Article  PubMed  PubMed Central  Google Scholar 

Hoshina A, Endo S. Anti-glomerular basement membrane glomerulonephritis concurrent with membranous nephropathy and acute tubular interstitial nephritis in a lung cancer patient treated with pembrolizumab. CEN Case Rep. 2022;12:230–6. https://doi.org/10.1007/s13730-022-00750-x.

Article  PubMed  PubMed Central  Google Scholar 

Javaugue V, Watson MJ, Fervenza FC, Nasr SH. Atypical antiglomerular basement membrane nephritis following immune checkpoint inhibitor. Kidney Int Rep. 2022;7:1913–6.

Article  PubMed  PubMed Central  Google Scholar 

Tani T, Sugino K, Hashimoto K, Mii A, Kashiwagi T, Shimizu A, et al. Concomitant anti-GBM glomerulonephritis and acute interstitial nephritis following programmed death receptor-1 blockade with nivolumab. Kidney Int Rep. 2022;7:2317–8.

Article  PubMed  PubMed Central  Google Scholar 

El Yamani N, Cote G, Riopel J, Marcoux N, Mac-Way F, Philibert D, et al. Pembrolizumab-induced anti-GBM glomerulonephritis: a case report. Kidney Med. 2023;5: 100682.

Article  PubMed  PubMed Central  Google Scholar 

Reynolds J, Tam FW, Chandraker A, Smith J, Karkar AM, Cross J, et al. CD28-B7 blockade prevents the development of experimental autoimmune glomerulonephritis. J Clin Invest. 2000;105:643–51.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kitching AR, Huang XR, Ruth A-J, Tipping PG, Holdsworth SR. Effects of CTLA4-Fc on glomerular injury in humorally-mediated glomerulonephritis in BALB/c mice. Clin Exp Immunol. 2002;128:429–35.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Reynolds J, Sando GS, Marsh OB, Salama AD, Evans DJ, Cook HT, et al. Stimulation of the PD-1/PDL-1 T-cell co-inhibitory pathway is effective in treatment of experimental autoimmune glomerulonephritis. Nephrol Dial Transplant. 2012;27:1343–50.

Article  PubMed  CAS  Google Scholar